Erectile dysfunction future or investigational therapies
Jump to navigation
Jump to search
|
Erectile dysfunction Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Erectile dysfunction future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Erectile dysfunction future or investigational therapies |
|
FDA on Erectile dysfunction future or investigational therapies |
|
CDC on Erectile dysfunction future or investigational therapies |
|
Erectile dysfunction future or investigational therapies in the news |
|
Blogs on Erectile dysfunction future or investigational therapies |
|
Risk calculators and risk factors for Erectile dysfunction future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Future or Investigational Therapies
Controversial and Unapproved Treatments
- Naltrexone
- Drug used for treating drug addicts can have some success in patients with inhibited sexual desire.
- Bremelanotide
- The experimental drug bremelanotide (formerly PT-141) does not act on the vascular system like the former compounds but allegedly increases sexual desire and drive in males as well as females. It is applied as a nasal spray. Bremelanotide allegedly works by activating melanocortin receptors in the brain. It is currently in Phase IIb trials.
- Melanotan II
- Like bremelanotide the experimental drug Melanotan II does not act on the vascular system either but increases libido. Melanotan II works by activating melanocortin receptors in the brain.
- hMaxi-K
- hMaxi-K is a form of gene therapy using a plasmid vector that expresses the hSlo gene, that encodes the alpha-subunit of the Maxi-K channel. It has undergone phase I safety trials.[1]
- Ginseng
- A double-blind study appears to show evidence that ginseng is better than placebo:[2] see the ginseng article for more details.
- Enzyte
- Enzyte is a product that has been advertised by saturation coverage on television channels such as CourtTV. However, the Center for Science in the Public Interest (CSPI) has filed a complaint with the Federal Trade Commission (FTC) about Enzyte for deceptive advertising. It is manufactured by Berkeley Nutritionals, which is alleged to be the subject of an investigation by the Attorney General of Ohio and the defendant in class-action lawsuits.
- Enzyte is a supplement that claims to increase the male libido or frequency of erections of the penis. Commercials for Enzyte are shown regularly on television. These commercials feature a man named Bob who never stops smiling, apparently because he had taken Enzyte and improved the size of his sex organs. The commercials are riddled with symbolic Phallic symbol|phallic imagery, e.g. golf clubs, remarkably tall glasses of iced tea, and a hose spraying barely a trickle of water (carried by someone who doesn't use Enzyte).
- The effectiveness of Enzyte is in dispute. Some medical professionals in fact advise against taking Enzyte, saying that it can lead to damage. The Center for Science in the Public Interest have urged the Federal Trade Commission to disallow further television advertising for Enzyte due to a lack of proper studies supporting claims. Enzyte maker Berkeley Premium Nutraceuticals, Inc., is currently under a class action lawsuit for false advertising.
- Enzyte is said to contain: Tribulus terrestris; Yohimbe Extract; Niacin; Epimedium; Avena sativa; zinc oxide; maca; Muira Pauma; Ginkgo biloba; L-Arginine; Saw Palmetto. Other ingredients: gelatin, rice bran, oat fiber, magnesium stearate, silicon dioxide.
- Herbal and other alternative treatments
- These are generally ineffective when tested blind, but may be useful for their psychological (placebo) effect: if a good result is expected, any highly praised, and often expensive, treatment can be effective. Reputable drugs can also benefit from the same effect.
References
- ↑ Melman A, Bar-Chama N, McCullough A, Davies K, Christ G (2005). "The first human trial for gene transfer therapy for the treatment of erectile dysfunction: preliminary results". Eur Urol. 48 (2): 314–8. PMID 15964135.